Image

The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors

The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

Walking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming increasingly common in clinical settings, with various design modes available. However, the effectiveness of new products in improving gait or motor function still requires further investigation.

This study aims to evaluate the usability and therapeutic effects of a new end-effector exoskeleton robot system, HIWIN MRG-P110, for gait training in chronic stroke patients. The system uses foot pedal mechanisms to drive hip and knee movements for lower-limb training. Unlike its predecessor, this device allows adjustment of the active assistance ratio, encouraging users to engage in voluntary movement. It is designed for gait training in stroke patients and others with neurological impairments, but the usability and efficacy of this new training model remain to be verified.

This clinical trial is a randomized, single-blind, prospective study enrolling 60 stroke patients who are 6 months to 3 years post-onset and have a Functional Ambulation Category (FAC) level of 0 to 3. The study will explore how patients with varying degrees of motor weakness learn to adapt to the "active-assistive mode" in terms of speed and perception. Participants will be randomly assigned to either the active-assistive mode group or the fully passive mode group. Both groups will receive 15 treatment sessions over 5 weeks.

The study will compare the two groups in terms of:

  1. Improvements in gait and balance immediately post-treatment and at 3-month follow-up
  2. Changes in brain activity, as measured by functional near-infrared spectroscopy (fNIRS)

Eligibility

Inclusion Criteria:

  • Aged between 18 and 80 years old.
  • First-ever stroke, confirmed by brain CT or MRI, with onset between 6 months and 3 years prior to enrollment.
  • Walking ability classified as Functional Ambulation Category (FAC) level 0 (non-ambulatory) to level 3 (able to walk short distances indoors or outdoors only).
  • Prior to the current stroke, the participant was an independent community ambulator without mobility impairments.

Exclusion Criteria:

  • Presence of lower limb joint contractures, deformities, or severe spasticity (Modified Ashworth Scale score of 4).
  • Lower limb musculoskeletal conditions causing wounds, pain, inability to bear weight, or significant leg length discrepancy (>2 cm after orthotic correction).
  • Known osteoporosis (T-score < -2.5) or history of osteoporotic fractures in the thoracolumbar spine or hip joints.
  • Inability to use the exoskeleton device due to body size, including:

Body weight > 135 kg; Height < 145 cm or > 190 cm Thigh length < 38 cm or > 48 cm; Calf length < 48 cm or > 52 cm

  • Cognitive or communication impairments that prevent understanding of study instructions or completion of questionnaires.
  • Acute infections or unstable vital signs.
  • Significant orthostatic hypotension or inability to maintain upright posture for more than 30 minutes.
  • Use of indwelling urinary catheter, nasogastric tube, or tracheostomy.
  • Pregnant women.
  • Terminal illness with life expectancy less than six months.
  • Inability to attend 15 rehabilitation sessions and follow-up assessment at 3 months.

Study details
    Stroke
    Rehabilitation
    Robotic Rehabilitation

NCT07034521

National Taiwan University Hospital

30 June 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.